🔗 Share this article

While the United States proceeds with unprecedented adjustments to its vaccination recommendations, an unexpected name has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who first made her name by expressing skepticism about coronavirus vaccinations throughout the global health crisis and has concentrated on alleged fatalities after Covid vaccination in her short time at the FDA.

Scheduled Shifts to Pediatric Vaccine Program

Health officials were set to announce radical changes to the pediatric immunization program earlier this month, synchronizing the US with the Danish immunization schedule, sources say – a substantial departure that would put the US at odds with many the global community with little proof for benefit. The planned update has been pushed back until the next year.

In place of Vinay Prasad, Tracy Beth Høeg is listed to speak at the event. She was just designated acting director of the FDA’s drug evaluation center, the fifth person to head the division this year.

A New Direction at the Regulatory Body

This interim role might represent a strengthened alliance between the pharmaceutical and vaccine branches as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it suggests a increased emphasis upon dismantling long-standing immunizations at the FDA.

Dr. Høeg has often pushed for ending certain pediatric shot schedules in the US in order to be more similar to Denmark's approach, a country with nationalized medicine and a number of inhabitants roughly the size of the state of Wisconsin.

In her initial statements, she has continued to focus on vaccination policy – typically the purview of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to medication approval.

Concerns Over Qualifications

Høeg has no obvious track record in medication creation, oversight or leadership, which has been customary for former heads of the CBER. She has served at the FDA as a top consultant to the agency head and the vaccine center since March.

“She doesn’t seem to have the requisite experience” for overseeing the pharmaceutical oversight division, stated Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in managing a major agency. She is not an expert in drug approvals.”

Former directors of the center would “be deeply familiar with regulatory frameworks and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Objectively, she lacks the kind of background that former directors who led the center have had.”

CDER has an vast workload at the FDA, the former commissioner emphasized.

“The public just pays attention on the new drug program, but the generic program authorizes a multitude of off-brand pharmaceuticals. There is also a biosimilars division, over-the-counter program and other areas, and each of these must be supervised,” Dr. Woodcock explained. “The responsibility you overlook, that is the part that I always told people is going to bite you.”

Additionally, a significant administrative element to the job, which oversees over 5,000 personnel. “It is a enormous administrative position, if you do it right,” Woodcock said.

Official Statement and Controversial Programs

Regarding questions about Høeg’s credentials and whether this appointment represents more teamwork among agency officials on vaccines, a press secretary said that the “questions are based on flawed presumptions”.

“This background matches the responsibilities of her position,” the official stated, pointing to the time Høeg spent advising the FDA commissioner on “drug safety and approval science, including computational safety modeling and shot safety tracking”.

As acting director, Høeg assumes responsibility for the commissioner’s controversial fast-track approval initiative, a contentious rapid therapy clearance system that reportedly worried her preceding directors. “By what process are these medications being picked for this expedited pathway? Who makes the choices?” Dr. Howard said. “There’s a lot of lack of transparency happening at the agency right now.”

Overall, he remarked, “the agency appears to be shifting towards less stringent regulations of pharmaceuticals, except for shots.”

Established History on Immunizations

Regarding immunizations, Dr. Høeg has a clearer, if problematic, history, critics said. She released a research paper using unverified volunteer-provided data to estimate the rate of myocarditis after Covid immunization. She advised the Florida surgeon general Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccinations are riskier than they are.

Part of her “wish list” for the current government encompassed altering rules for recently developed shots and ending “optional” immunizations, she remarked post-election on a podcast. At the FDA, Høeg has reportedly floated the idea of preventing adolescent males from getting Covid vaccinations.

“She is an all-around true believer who begins with her conclusions and reverse-engineers to fit the evidence in a very disingenuous, fraudulent fashion,” Howard argued.

Gaining Influence and a “Push for Payback”

Høeg became part of fellow dissenters, {like|